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Abstract
Objective: The cytotoxic T lymphocyte associated antigen-4 (CTLA-4) is expressed on T lymphocytes, and inhibits 
the T-cell responses. In animal models, it has been shown that complete CTLA-4 deficiency was lethal due to mas-
sive infiltration of tissues by polyclonally proliferating lymphocytes. CTLA-4 A49G polymorphism, which has been 
suggested to reduce the inhibitory function of the CTLA-4 molecule, was found to be associated with various auto-
immune diseases in recent studies. 
Material and Methods: In this study, we evaluated the frequency of CTLA-4 A49G polymorphism in 46 patients 
with autoimmune hemolytic anemia (AIHA), 62 patients with immune thrombocytopenic purpura (ITP), and 150 
healthy individuals. 
Results: Allele frequencies and genotype distributions were similar in both ITP and AIHA patients compared to 
healthy individuals. In subgroup analysis, however, we found that in chronic lymphocytic leukemia (CLL) patients 
with AIHA (n=4), all patients had CTLA-4 A49G polymorphism (3 had AG, 1 had GG). There was no significant 
statistical association between G allele and systemic lupus erythematosus (SLE) or AIHA.
Conclusion: These data suggest that CTLA-4 A49G polymorphism does not contribute to the pathogenesis of 
lymphoproliferative diseases itself, nor does it increase the risk of autoimmune complications in patients with 
lymphoproliferative disease. (Turk J Hematol 2010; 27: 78-81)
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Özet
Amaç: Sitotoksik T lenfosit antijen-4 (CTLA-4) ifadesi T lenfositlerde gerçekleşir ve T hücre cevabını engeller. Hayvan 
modellerinde CTLA-4 yokluğunun, dokuların poliklonal çoğalan lenfositler tarafından yoğun infiltrasyonu nedeni ile, 
ölümcül olduğu gösterilmiştir. Farklı otoimmün hastalıklar ile ilişkilendirilmiş CTLA-4 A49G polimorfizminin, CTLA-4 
molekülünün inhibitör fonksiyonunu azalttığı düşünülmektedir.
Yöntem ve Gereçler: Bu çalışmada otoimmun hemolitik anemi (OIHA) hastası 46 kişi, immun trombositopenik 
purpura (ITP) hastası 62 kişi ve 150 sağlıklı kontrol bireyinde CTLA-4 A49G polimorfizmi çalışılmıştır. Introduction
Autoimmune disorders are the result of disturbed immune 
tolerance to self-antigens. After the presentation of an antigen 
in conjunction with HLA molecules on the surface of an anti-
gen-presenting cell to a specific T-cell receptor (TCR), co-
stimulatory signals are required for the T-cell responses [1]. A 
number of co-stimulatory molecules are present on the T-cell 
membrane, which may have stimulatory or inhibitory effects on 
T lymphocytes. The cytotoxic T lymphocyte associated anti-
gen-4 (CTLA-4) is expressed on T lymphocytes and inhibits the 
T-cell responses [2]. Mechanisms of down-regulation of T-cell 
immunogenic response by CTLA-4 may be due to competitive 
antagonism with CD28, increment in TCR stimulation thresh-
old, and limitation of T-cell division capacity and activation of 
cell cycle arrest of T-cells after antigenic stimulation [2]. In ani-
mal models, it has been shown that complete CTLA-4 defi-
ciency was lethal due to severe lymphoproliferative disorders 
with massive infiltration of tissues by polyclonally proliferating 
lymphocytes [3]. Blocking the CTLA-4/B7 interaction by mono-
clonal antibodies results in an increase in antigen-specific 
T-cell proliferation, whereas enhancing the inhibitory function of 
CTLA-4 suppresses T-cell responses [1,2].  These findings 
provide strong evidence that CTLA-4 has a crucial role in the 
negative regulation of T-cell responses.
The CTLA-4 gene is located on chromosome 2 (2q33). 
Several polymorphisms were identified on the CTLA-4 gene 
[4]. The A49G polymorphism in exon 1 of the CTLA-4 gene is 
especially important because it alters the structure of the 
CTLA-4 protein by causing Thr17Ala amino acid substitution 
[5]. It has been suggested that this polymorphism reduces the 
inhibitory function of CTLA-4 [2]. In recent studies, the CTLA-4 
A49G polymorphism was found to be associated with autoim-
mune diseases such as insulin-dependent diabetes, rheuma-
toid arthritis, systemic lupus erythematosus (SLE), multiple 
sclerosis, primary biliary cirrhosis, Hashimoto’s thyroiditis, and 
Graves’ disease [1,2,4,6]. In this study, we evaluated the fre-
quency of the CTLA-4 A49G polymorphism in patients with 
autoimmune hemolytic anemia (AIHA) and autoimmune throm-
bocytopenic purpura (ITP).
Materials and Methods
Participants:  The present study was approved by the 
local ethics committee (Istanbul Faculty of Medicine) and all 
participants gave informed consent. Patients were selected 
from cases admitted to the Hematology Division of the Istanbul 
Faculty of Medicine from May 2003 to June 2006. One hun-
dred and fifty healthy Turkish subjects, 46 patients with AIHA 
and 62 patients with ITP were included in our study. ITP and 
AIHA patients were diagnosed by standard methods and were 
being followed by the Hematology Department. 
In the AIHA group, median age was 53 (28-66) and male to 
female ratio was 13/33. Fourteen AIHA patients also had SLE, 
4 had chronic lymphocytic leukemia (CLL), 2 had Evans’s syn-
drome, and 2 had autoimmune diseases other than SLE (auto-
immune thyroiditis and autoimmune hepatitis). 
In the ITP group (n=62), median age was 41 (18-56) and 
male to female ratio was 17/45. Thirty-six patients had primary 
ITP. Twenty-six patients in the ITP group had antiphospholipid 
antibodies (aPLA), and 12 of those patients were diagnosed as 
definite antiphospholipid syndrome (with thrombosis and/or 
pregnancy morbidity). Fourteen ITP patients had only persis-
tent aPLA-positivity.
In the healthy control group (n=150), median age was 38 
years (18-55), and male to female ratio was 67/83. 
Methods: Genomic DNA was isolated from peripheral 
venous blood samples using high pure polymerase chain reac-
tion (PCR) template preparation kit (Roche Diagnostics). 
For the amplification of exon 1 to show CTLA-4 A49G 
polymorphism, 5’-GCTCTACTCCTGAAGACCT-3’  and 
5’-AGTCTCACTCACTCACTTTGCAG-3’  primers were used. 
Amplified DNA samples were digested by Bbv I restriction 
endonuclease enzyme (New England Biolabs, Beverly, MA). 
Amplified fragment (162 bp) analyzed on 3.5% agarose gel was 
stained by ethidium bromide. The allele A was not cut by the 
enzyme and so left 162 bp; on the contrary, G allele was cut into 
two DNA fragments 88 and 74 bp long [4].
Statistical Analysis: Statistical analysis was performed 
using chi-square and Fisher’s exact tests at ‘Graphpad for 
Windows Version 3.0’. P values <0.05 were accepted as sta-
tistically significant. Results of the statistical analysis of com-
parisons of the allele frequencies are shown in Table 1.
Results 
Healthy Controls: One hundred and fifty healthy subjects 
were investigated in terms of CTLA-4 A49G polymorphism. 
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Bulgular: ITP ve OIHA hastalarından oluşan iki grupta da sağlıklı kontrol bireyleri ile karşılaştırıldığında benzer allel 
frekansları ve genotip dağılımları saptanmıştır. Alt grup analizi gerçekleştirildiğinde ise hem OIHA hem de KLL has-
talığına sahip 4 bireyin hepsinin polimorfizme sahip olduğu gösterilmiştir (3 AG, 1 GG). Risk alleli olan G OIHA, İTP 
ve kontrol grubunda incelendiğinde istatistik olarak anlamlı bir farklılık saptanmamıştır. 
Sonuç: Bu verilerin ışığında CTLA-4 A49G polimorfizminin lenfoproliferatif hastalıkların patogenezine bir katkısının 
olmadığı veya lenfoproliferatif hastalığa sahip bireylerde otoimmün komplikasyonların gelişmesi açısından risk oluştur-
madığı sonucuna varılmıştır. (Turk J Hematol 2009; 27: 78-81) 
Anahtar kelimeler: Sitotoksik T lenfosit antijen-4 (CTLA-4), A49G polimorfizmi, otoimmünite, idiopatik trombosito-
penik purpura, otoimmün hemolitik anemi, kronik lenfositik lösemi
Geliş tarihi: 26 Aralık 2008    Kabul tarihi: 22 Şubat 2010Genetic variation was distributed according to Hardy-Weinberg 
equilibrium. Genotype frequencies were 48% for AA, 47.3% for 
AG and 4.7% for GG. A-allele frequency was 71.6% and 
G-allele frequency was 28.4% (Table 1). There was no statisti-
cal difference between genders and allele frequencies in the 
healthy control group.
AIHA Group: Twenty-one patients had AA (45.6%), 21 had 
AG (45.6%), and 4 had GG (8.8%) genotype in this group. 
A-allele frequency was 68.4% and G-allele frequency was 
31.6%, which was similar to healthy controls. In sub-group 
analysis, in a small group of patients with CLL and AIHA (n=4), 
all patients were found to have CTLA-4 A49G polymorphism 
(3 had AG, 1 had GG) (Table 1). When we statistically com-
pared the risk allele G in the AIHA and control groups, there 
was no statistical difference (p=0.643; odds ratio [OR]: 0.858; 
95% confidence interval [CI]: 0.8658-2.33). In sub-group 
analysis, we found no difference between patients and controls 
for the risk allele G (Table 1).
ITP Group: Thirty-eight had AA (61.3%), 21 had AG 
(33.9%), and 3 had GG (4.8%) genotype in this group. A-allele 
frequency was 78.4% and G-allele frequency was 21.6%. 
There was no statistical difference between the ITP group and 
healthy control group for the risk allele. In sub-group analysis, 
we similarly found no difference between ITP patients and con-
trols for the risk allele G.
Discussion
The role of the CTLA-4 A49G polymorphism in the develop-
ment of autoimmune diseases is not well understood. Since 
CTLA-4 controls the amplitude of immune response and periph-
eral tolerance, this polymorphism could have an impact on 
autoimmunity in some way. The CTLA-4 A49G polymorphism 
may result in susceptibility to autoimmune disease [1,2,6,7]. 
The role of the CTLA-4 A49G polymorphism in the develop-
ment of autoimmune blood diseases such as ITP and AIHA is 
not clear. In the only published study, which was done by 
Pavkovic et al. [5], it was shown that the CTLA-4 A49G polymor-
phism was significantly higher in patients with AIHA, but no 
association was found in patients with ITP. They also showed 
that the G-allele frequency was highest among CLL patients 
who had developed AIHA. In that study, 60% of the AIHA cases 
were patients with CLL. Our study is the second study investi-
gating the role of the CTLA-4 A49G polymorphism in patients 
with ITP and AIHA. Although we could not demonstrate an 
association between autoimmune blood diseases and the 
CTLA-4 A49G polymorphism, we found very interesting results 
in the CLL+AIHA subgroup, as in Pavkovic’s study. In our study, 
all CLL patients who had AIHA (n=4) were found to have G allele 
(3 had AG, 1 had GG). With the knowledge of the development 
of fatal lymphoproliferative disease in CTLA-4-deficient mice, 
these data suggest that the CTLA-4 A49G polymorphism may 
contribute to the pathogenesis of the lymphoproliferative dis-
eases itself, or may increase the risk of autoimmune complica-
tions in patients with lymphoproliferative diseases. In a meta- 
analysis study, Lee et al. [6] demonstrated a significant statistical 
association between the A49G polymorphism and SLE suscep-
tibility. Their meta-analysis did not show a significant association 
of other polymorphisms of CTLA-4 with SLE. Though the esti-
mated ORs from the race-specific analysis were very similar, a 
statistically significant SLE association was found with Asians 
only (n=522). Similarly, in our study, there was no association 
between the A49G polymorphism and SLE in the Caucasian 
population based on this meta-analysis. When we statistically 
compared groups, there was no association between the AIHA 
and control group. In contrast to Lee et al. [6], in the present 
study, our findings demonstrated that there was no significant 
statistical association between G allele and SLE. Similar findings 
were seen for ITP (Table 1). 
In conclusion, our results showed that there is no associa-
tion between the A49G polymorphism of the CTLA-4 gene and 
AIHA or ITP disease. Further genetic and clinical studies are 
required to understand the exact role of the CTLA-4 A49G 
polymorphism in the development of autoimmune and lympho-
proliferative diseases. 
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Table 1. Patient and control genotype and allele frequencies for the CTLA-4 A49G polymorphism
  n   AA  AG  GG  Allele A  Allele G  p (vs *)  OR  95% CI
Total AIHA  46  21  21  4  63  29  0.643  0.85  0.517-1.425
Primary AIHA  28  15  11  2  41  15  0.874  1.08  0.568-2.055
SLE+AIHA  14  6 7 1  19  9  0.660 0.83  0.363-1.918
CLL+AIHA  4  0 3 1  3  5  0.049 0.23  0.055-1.015
Total ITP  62  38  21  3  97  27  0.183  1.42  0.865-2.333
Primary ITP   36  23  13  0  59  13  0,1004  1.79  0.935-3.441
aPLA+ ITP  26  15  8  3  38  14  1.000  1.07  0.553-2.081
Healthy individuals*  150  72  71  7  215  85  -  -  -
AIHA: Autoimmune hemolytic anemia; SLE: Systemic lupus erythematosus; CLL: Chronic lymphocytic leukemia; ITP: Immune thrombocytopenic purpura; aPLA: 
Antiphospholipid antibodies; OR: Odds ratio; CI: Confidence intervalReferences
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